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Abstract
Tryptophan is required for T lymphocyte effector functions. Its degradation
is one of the mechanisms selected by tumors to resist immune destruction.
Two enzymes, tryptophan-2,3-dioxygenase and indoleamine 2,3-dioxygenase
1, control tryptophan degradation through the kynurenine pathway. A third
protein, indoleamine 2,3-dioxygenase 2, was identified more recently. All three
enzymes were reported to be expressed in tumors, and are candidate targets
for pharmacological inhibition aimed at restoring effective anti-tumoral immunity.
In this review, we compare these three enzymes in terms of structure, activity,
regulation, and expression in healthy and cancerous tissues, in order to
appreciate their relevance to tumoral immune resistance.
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Tryptophan is required for T lymphocyte effector functions. Its degradation is one of the
mechanisms selected by tumors to resist immune destruction.Two enzymes, tryptophan-
2,3-dioxygenase and indoleamine 2,3-dioxygenase 1, control tryptophan degradation
through the kynurenine pathway. A third protein, indoleamine 2,3-dioxygenase 2, was iden-
tified more recently. All three enzymes were reported to be expressed in tumors, and are
candidate targets for pharmacological inhibition aimed at restoring effective anti-tumoral
immunity. In this review, we compare these three enzymes in terms of structure, activity,
regulation, and expression in healthy and cancerous tissues, in order to appreciate their
relevance to tumoral immune resistance.
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INTRODUCTION
In the last decade, tryptophan catabolism has emerged as a
powerful mechanism of peripheral immune tolerance, contribut-
ing to maintain homeostasis by preventing autoimmunity or
immunopathology that would result from uncontrolled and
overreacting immune responses. This is achieved through the
action of enzymes catalyzing the first and rate-limiting step of
tryptophan degradation along the kynurenine pathway, includ-
ing indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan-2,3-
dioxygenase (TDO). As a result, tryptophan is locally depleted
while tryptophan catabolites accumulate, including kynurenine
and its derivatives, depending on the presence of downstream
enzymes in the kynurenine pathway. Although IDO1 and TDO
are located in the cytosol, the metabolic modifications they induce
extend to the extracellular microenvironment because tryptophan
and kynurenine derivatives readily cross the plasma membrane
through specific transporters (1–3). These metabolic modifica-
tions result in a local microenvironment becoming profoundly
immunosuppressive, as a result of various mechanisms whose
respective role remains incompletely characterized. A first mech-
anism is based on tryptophan depletion: T lymphocytes are
extremely sensitive to tryptophan shortage, which causes their
arrest in the G1 phase of the cell cycle (4). This is due, at least
partly, to the induction of an integrated stress response triggered by
GCN2, a stress kinase that is activated by elevations in uncharged
tRNAs (5). Tryptophan shortage can also stop T-cell proliferation
through inactivation of the mTOR pathway (6). A second mech-
anism depends on the accumulation of tryptophan catabolites:
some of them, such as 3-hydroxyanthranilic and quinolinic acids,
Abbreviations: DC, dendritic cells; IDO1, indoleamine 2,3-dioxygenase 1; IDO2M,
indoleamine 2,3-dioxygenase 2; IFNγ, interferon-gamma; MoDC, monocyte-
derived DC; TDO, tryptophan-2,3-dioxygenase.
can induce T-cell apoptosis (7, 8), while other kynurenine deriv-
atives can induce the differentiation of regulatory T-cells (9),
possibly through activation of the aryl hydrocarbon receptor
(AhR) (10).
One of the key hallmarks of cancer is the ability to evade
immune destruction (11). To do so, tumors often hijack one or
several of these tryptophan-catabolizing enzymes endowed with
immunosuppressive properties. The best studied enzyme in this
respect is IDO1. In 2003, our group showed for the first time
that IDO1 was expressed in human tumors, and that, in a mouse
tumor model, IDO1 protected tumors against immune rejection,
an effect that could be reversed by pharmacological IDO1 blockade
(12). Numerous subsequent studies have confirmed these find-
ings and demonstrated, in mouse models, the benefit of IDO1
inhibitors, either alone or in combination with chemotherapy (13,
14). Several IDO1 inhibitors currently undergo clinical develop-
ment. More recent work from our group demonstrated that also
TDO was expressed in human tumors and showed a similar tumor-
protective effect against immune rejection (15). Tumor rejec-
tion was restored by pharmacological TDO inhibition, making
TDO a second attractive target for cancer therapy. More recently,
indoleamine 2,3-dioxygenase 2 (IDO2), a third enzyme poten-
tially involved in tryptophan catabolism, was identified through
its high homology with IDO1 (16, 17). Its precise activity and its
involvement in tumoral immune resistance have not been clearly
established.
Tryptophan-2,3-dioxygenase, IDO1, and possibly IDO2 cat-
alyze the same reaction of oxidative breakdown of the indole
group of tryptophan. However, they differ in a number of impor-
tant aspects such as structure, activity, regulation, and tissular
expression. In this review, we discuss the aspects of these enzymes
that are relevant to their potential immunosuppressive role in the
context of tumoral immune resistance, in view of recent data
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highlighting their expression profile in normal and cancerous
human tissues.
TRYPTOPHAN-2,3-DIOXYGENASE
Tryptophan-2,3-dioxygenase is a 167 kDa tetrameric heme-
containing enzyme with constitutive and specific l-tryptophan-
catabolizing activity. It is selectively expressed in the liver, where
it regulates the levels of blood tryptophan. Consistent with this
regulatory function, human TDO has a Km of 190µM for l-
tryptophan,which allows it to efficiently degrade this amino acid at
concentrations above its physiological level (around 80µM) (18).
As the main enzyme responsible for the metabolism of dietary
tryptophan, TDO is positively regulated by tryptophan, which dra-
matically increases TDO expression and/or activity when present
in the blood at supraphysiological concentrations (19). These
features appear optimized to fulfill the main function of TDO,
i.e., to maintain tryptophan homeostasis. This principal function
of TDO was confirmed by the observation of a 10-fold increased
tryptophan level in the blood of TDO-knockout as compared to
wild-type mice (20).
As compared to liver, the expression of TDO in other normal
tissues is negligible. This is illustrated on Figure 1A,where we com-
piled whole transcriptome data from the Genome Tissue Expres-
sion project (GTEx)1 (21). In contrast, a number of human tumors
express significant levels of TDO. Figure 1A also shows a compi-
lation of TDO2 expression data in 9,169 human tumors, retrieved
from whole transcriptome data from The Cancer Genome Atlas
(TCGA)2 (22). Importantly, we used the same approach (DESeq)
(23) to normalize the RNA-Seq data from normal and tumoral
tissues, so as to allow comparison of expression levels, despite the
distinct origins of the two data sets.
As expected because of its expression in normal liver, TDO2 is
expressed at high levels in hepatocarcinoma (Figure 1A). It is also
expressed in many other tumor types, although at weaker levels
and only in a fraction of the samples. These data are in line with
published RT-qPCR data obtained in a smaller series of human
tumor samples (15), and corroborate reported findings of consti-
tutive TDO expression in a number of established human tumor
cell lines of various histologies, including glioblastoma, colorectal
carcinoma, head-and-neck carcinoma, and gallbladder carcinoma
(15, 24). The precise cell type(s) expressing TDO in liver and
tumors remain(s) to be identified, awaiting the availability of a
reliable validated antibody.
Given the immunosuppressive effect of tryptophan catabolism,
this TDO expression in human tumors prompted us to evaluate
whether TDO favors tumor growth by promoting resistance to
immune rejection. Due to the lack of mouse tumors naturally
expressing TDO, we resorted to TDO-transfected tumor lines,
and observed that TDO-positive P815 tumors were no longer
rejected by mice immunized against P1A, a MAGE-type tumor
antigen naturally expressed by this mastocytoma (15). Moreover,
based on a previously published scaffold (25), we developed a new
TDO inhibitor with a better bioavailability after oral administra-
tion (26), and observed that mice treated with this compound
1http://www.gtexportal.org
2http://cancergenome.nih.gov
recovered their ability to reject TDO-expressing tumors (15). The
treatment was not associated with any noticeable toxicity nor ele-
vation of liver enzymes. These results made the proof of concept
for the use of TDO inhibitors as immune modulators for can-
cer therapy. In parallel, another group provided evidence for a
tumor cell autonomous effect of TDO expression in glioblastoma,
promoting tumor progression through AhR activation by tryp-
tophan catabolites, resulting in increased tumor cell survival and
motility, and reduced anti-tumor immune responses (24). The
notion that the effects of TDO on tumor growth and anti-tumor
immunity would be primarily mediated by tryptophan catabo-
lites – as opposed to tryptophan depletion – fits with the high Km
of TDO for tryptophan, which makes this enzyme more apt at
producing significant amounts of tryptophan catabolites than at
depleting tryptophan down to the submicromolar levels needed
to impair T-cells.
Besides IDO, these results establish TDO as another immuno-
suppressive enzyme involved in tumor progression, and make it
a promising drug discovery target. In addition, the high expres-
sion of TDO in the liver raises interesting questions regarding its
potential immunosuppressive role in this organ. Liver is known
as an immune tolerant organ: as opposed to other transplanted
tissues, HLA-mismatched liver allografts are usually well tolerated
in humans and require less immunosuppressive therapy (27). It
will be interesting to evaluate whether TDO plays a role in this
phenomenon and to determine whether TDO inhibition could
alter the course of liver infections, primary liver tumors, or liver
metastases. In line with the notion of a protective effect of TDO
against excessive liver immunity and/or inflammation, TDO was
recently found to play a key role in the protection against endo-
toxic shock: TDO-knockout mice died after injection of a LPS
dose that was only sublethal in wild-type animals (28). Interest-
ingly, AhR-knockout mice were equally sensitive to sublethal LPS,
in line with the notion that a tryptophan catabolite produced by
TDO – possibly kynurenine – was responsible for the protective
effect by activating AhR.
INDOLEAMINE 2,3-DIOXYGENASE 1
Indoleamine 2,3-Dioxygenase has been known for more than four
decades as an intracellular tryptophan-degrading enzyme whose
expression is strongly induced by IFNγ in most cells. Although
IDO1 catalyzes the same reaction as TDO, the two enzymes are
unrelated in terms of primary structure and also differ in qua-
ternary structure. Both are heme-containing enzymes requiring
a reduced iron atom in the catalytic site, but IDO1 functions as
a monomer while TDO is a tetramer of four heme-containing
subunits (29). The enzymes further differ in terms of expression
profile (see below) and substrate specificity, with IDO1 acting on
a larger variety of substrates of the indoleamine family. Lastly,
IDO1 has a much lower Km for tryptophan (about 20µM), mak-
ing this enzyme able to significantly deplete tryptophan down to
the submicromolar range (30). As such IDO1 was long consid-
ered as one of the effector molecules of IFNγ, acting to limit the
growth of intracellular pathogens by depriving tryptophan. In the
late 90s, the immunosuppressive function of IDO1 was discovered
in mice by studying the placenta, which constitutively expresses
high levels of IDO1: tryptophan catabolism by placental IDO1 was
Frontiers in Immunology | Immunological Tolerance February 2015 | Volume 6 | Article 34 | 2
van
B
aren
and
Van
den
E
ynde
TD
O
,ID
O
1,and
ID
O
2
in
tum
ors
FIGURE 1 |TDO2, IDO1, and IDO2 gene expression in common human normal and tumoral
tissues (panels A, B and C, respectively). We used publicly available whole transcriptome data to
assess the expression of these three genes in large series of human normal and cancerous tissues.
We retrieved raw mRNA counts from the Genome Tissue Expression project (GTEx, see text
footnote 1) and The Cancer Genome Atlas (TCGA, see text footnote 2) databases, respectively,
normalized the values according to the DESeq approach (23), and represented the results as boxplot
graphs for each normal tissue and tumor type, using the R statistical software and the Bioconductor
package. The DESeq normalization approach allows to correct the data for the sequencing depth,
which affects the number of aligned reads to the gene. It (i) computes the geometric mean for each
gene; (ii) divides raw counts for each gene by the corresponding geometric mean; (iii) computes for
each sample the median of the obtained ratios; and (iv) divides each gene count by the computed
median for the sample. The vertical bars in each box represent, from left to right, the first quartile,
median, and third quartile of the indicated sample population. The left and right edge of the
horizontal line represents the minimum and maximum values, respectively, after exclusion of the
outliers, displayed as individual dots. Several (n=37) IDO1 outlier values >15,000 have been
omitted for the clarity and concision of the graphical display. This approach provides a robust mean
to assess the expression of specific genes in the context of malignant diseases, because RNA-Seq
data are more precise and have less background than microarray data, and because large series of
highly controlled data of various sample types are available from public databases. Carc, carcinoma;
H&N, head-and-neck; Paragang, paraganglioma.
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found instrumental in protecting the fetus from maternal immune
rejection (31). Subsequent studies amply confirmed this immuno-
suppressive role of IDO1, first in dendritic cells (DC), where IDO1
can be induced by a number of stimuli that drive DC toward
a tolerogenic program (32, 33), but also in tumors, which often
express IDO1 and thereby resist immune rejection (12). These
findings shed a new light on the function of IFNγ-induced IDO1:
more than an effector mechanism of IFNγ, IDO1 now appears as
part of a retrocontrol mechanism responsible for the termination
of immune responses and the prevention of immunopathology,
which would result from overreacting responses. Numerous pre-
clinical studies have subsequently documented the therapeutic
potential of IDO1 inhibitors in cancer therapy, either alone or in
combination with chemotherapy or immunotherapy (13, 14, 34).
Inhibition of the IDO1 pathway therefore represents a promising
therapeutic approach, and clinical trials evaluating the first IDO1
inhibitors have started. IDO1 inhibition does not cause obvious
toxicity in mouse models, and IDO1-knockout mice do not dis-
play abnormal phenotypic features (35, 36), suggesting that the
approach is safe. As expected, IDO1–KO mice displayed increased
sensitivity to the induction of inflammatory and autoimmune
reactions (on-target effects) (37). They also displayed pericardiac
calcifications, but this was observed in only 30% of females of
only one strain of mice (37). Because the IDO1 expression profile
differs between mouse and man, a better prediction of poten-
tial side effects of IDO1 inhibition requires a careful evaluation of
IDO1 expression in human tissues. We recently developed and val-
idated a new highly specific monoclonal antibody against IDO1,
and used it to perform an extensive profiling of IDO1 expres-
sion in normal and tumoral tissues by immunohistochemistry
(38). We discuss the main findings of this work in the following
paragraphs.
IDO1 EXPRESSION IN HUMAN NON-CANCEROUS TISSUES
In normal human tissues, the IDO1 protein was observed in
mature DC located in lymphoid organs, in some epithelial cells
of the female genital tract, as well as in endothelial cells of term
placenta and, surprisingly, lung parenchyma (38). These data are
consistent with the expression profile of the IDO1 transcript that
we obtained from the GTEx database using the same approach as
for TDO2 (Figure 1B). The IDO1 gene is weakly or not expressed
in most normal tissues, with the noticeable exception of lung. Note
that placenta and secondary lymphoid organs, which also contain
IDO1-expressing cells, were not represented in the GTEx data set
that we used.
Healthy non-lymphoid tissues
Indoleamine 2,3-Dioxygenase 1 is constitutively expressed in
human and mouse placenta. In the latter, its involvement in
fetal protection against maternal immune rejection has been
demonstrated experimentally (31). This function cannot be read-
ily extrapolated to human pregnancies, because the cell types that
express IDO1 differ between the two species. In the mouse, IDO1
expression was observed in trophoblast cells (35, 39) whereas in
human placenta it was found in endothelial cells (38,40). The func-
tional consequences of endothelial IDO1 expression in terms of
tryptophan degradation and immune protection are not known.
The same applies to lung endothelium. It is hard to consider that
tryptophan catabolism by cells exposed to the blood flow can
impose an immunosuppressive flavor to the microenvironment.
Therefore, a cell-intrinsic function is more likely. In this regard,
it is interesting to note that the density of the pulmonary vascu-
lature was reported to be reduced in IDO1-deficient as compared
to wild-type mice, suggesting a role for IDO1 in supporting lung
vascular development (41). In mice, inflammation-induced IDO1
expression in endothelial cells was also reported to induce vasodi-
lation and contribute to reduced blood pressure during severe
inflammation (42). Apart from IDO1 vascular expression, lung
and placenta have another exclusive feature in common. Both are
respiratory organs, in which the oxygen and carbon dioxide gra-
dients are inverted as compared to peripheral organs. Whether
there is a link between these two features, and whether these gra-
dients affect the redox status of IDO1, which controls its enzymatic
activity, is not known.
Constitutive expression of the IDO1 protein has also been
reported in epithelial cells from the female genital tract (38, 43). It
has been hypothesized that this expression helps fight genital infec-
tions through local depletion of tryptophan, required for pathogen
growth. In the mouse, one of the tissues with the highest expres-
sion of IDO1 is the epididymis. This specific tissular expression
was not observed in man (38).
Healthy lymphoid tissues
Interstitial cells expressing IDO1 were observed in human lym-
phoid tissues, including lymph nodes, spleen, tonsils, Peyers’s
patches, the gut lamina propria, and the thymic medulla (38).
These cells were further characterized in lymph nodes and lam-
ina propria, and were identified as mature conventional DC.
They all expressed maturation markers DC-LAMP and CD83,
and lacked markers of other DC or myeloid subtypes such as
CD1a, langerin, CD123, and CD163. In lymph nodes, about 50%
of mature conventional DC expressed IDO1, while neither plas-
macytoid DC (pDC) nor any other cell type did. This parallels the
IDO1 induction observed in vitro during maturation of human
monocyte-derived DC (MoDC), which happens during the ter-
minal phase of the DC maturation program, and likely represents
a negative feedback loop of retrocontrol of the immune response
(38). Various maturation stimuli can induce IDO1 in MoDC,
including LPS and the cocktail of cytokines [interleukin-(1)-beta,
interleukin-6, tumor necrosing factor-alpha, and prostaglandin-
E2 (PGE2)] commonly used to produce DC-based vaccines for
clinical immunotherapy (44). Among the cytokines present in this
maturation cocktail, PGE2 plays the key role for IDO1 induc-
tion (45). Interestingly, omitting PGE2 from the cytokine cocktail
results in fully mature MoDC lacking IDO1 expression, which
should be more efficient as a vaccine platform (38).
Elegant mechanistic studies have characterized the induction
and function of IDO1 in murine DC, particularly in pDC (46, 47).
These studies showed a key role for IDO1 in controlling tolerogenic
properties of pDC, and uncovered a complex regulation inte-
grating transcriptional induction of IDO1, proteasome-mediated
IDO1 degradation triggered under inflammatory conditions by
IL-6 and SOCS3, and IDO1-mediated signaling leading to long-
term tolerance via transforming-growth factor beta production. It
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is unclear at the present time whether those findings also apply to
human pDC, which do not express IDO1 (38, 48).
IDO1 EXPRESSION IN TUMORS
At the tumor site
Tumors have diverted the immunosuppressive function of IDO1
to their own benefit in their continued efforts to resist immune
rejection. A number of human tumor cell lines express IDO1 in
a constitutive manner, and most other tumor lines start express-
ing IDO1 when exposed to IFNγ (12). In human tumor samples,
IDO1 expression is commonly observed both at the RNA and pro-
tein levels (Figure 1B) (38, 49). Murine tumors expressing IDO1
are resistant to immunization-dependent rejection, a phenome-
non that can be partially reverted by IDO1 inhibition (12). In
human tumors, IDO1 expression usually correlates with a poor
prognosis and is linked to a more aggressive tumor phenotype, a
reduced tumor infiltrate, and an increased number of regulatory
T-cells at the tumor site (49).
Our recent immunohistochemistry study analyzed 866 human
tumors of 15 common types: about 56% expressed IDO1 (38).
There was a remarkable match between the hierarchy of our IDO1
protein expression profile per tumor type and that of the corre-
sponding mRNA retrieved from the TCGA database (Figure 1B).
In both datasets, endometrial and cervical carcinomas emerged
as the tumors with the highest and most frequent IDO1 expres-
sion, followed by kidney and lung carcinomas. The lowest values
were in both cases observed in glioblastomas. Three distinct cellu-
lar expression patterns emerged, individually or in combination.
IDO1 was expressed by tumor cells (20% of the samples), by inter-
stitial cells in lymphocyte-rich areas in the tumor stroma (46% of
the samples), or by endothelial cells (14% of the samples). Part of
the IDO1 expression by tumor cells might result from an ongoing
immune response involving T lymphocytes producing IFNγ. This
is exemplified by cervical carcinoma, where IDO1-positive tumor
cells were often located at the periphery of tumor nodules, which
were surrounded by T lymphocytes. This is reminiscent of the
expression profile observed for PD-L1, another protein involved
in tumoral immune resistance, which is also induced by IFNγ and
often observed in T-cell infiltrated tumors. This PD-L1 expression
profile, indicative of an adaptive resistance mechanism, was found
to predict clinical responses to PD1/PD-L1 blocking reagents (50–
52). In a similar manner, IDO1 expression in inflamed tumors
might also indicate an adaptive resistance mechanism. In line with
this, IDO1 expression in human melanoma was found to correlate
with T-cell infiltration (53). Moreover, and quite paradoxically,
IDO1 belongs to the group of genes whose expression in tumors
prior to immunotherapy is predictive of a better clinical response,
along with T-cell specific genes and other IFNγ-induced genes
(54). Here, the key predictive factor is most likely the presence of
tumor-infiltrating lymphocytes (TILs) inside the tumor,and IDO1
is secondarily induced in response to IFNγproduced by those TILs.
In our study mentioned above (38), the IDO1 expression that
was often observed in the tumor stroma also likely resulted from
adaptive resistance. Such a pattern was dominant, for example, in
colorectal carcinomas.
In contrast, a subset of tumors expressed IDO1 within tumor
cells in the absence of any inflammation. This is the case in
endometrial carcinomas, which often contain IDO1-expressing
tumor cells scattered within tumor nodules in the absence of obvi-
ous T-cell infiltration (38). Constitutive IDO1 expression is also
observed in a number of human tumor lines (12), and is likely
triggered by oncogenic events, whose characterization will be of
great interest (55). Tumor-intrinsic constitutive IDO1 expression
might contribute to tumoral immune resistance by preventing
T-cell infiltration, a mechanism conceptually different from adap-
tive resistance, where IDO1 expression would represent a negative
feedback mechanism induced by the T-cell response. Intriguingly,
constitutive IDO1 expression has not been observed in murine
tumors so far. Many murine tumors (with the notable exception
of B16 melanoma) express IDO1 upon exposure to IFNγ, but
none of them expresses IDO1 in the absence of IFNγ. Therefore,
preclinical models commonly used to evaluate IDO1 inhibitors
investigate IDO1-related adaptive resistance but not intrinsic resis-
tance (13). The latter, which is relevant to the human situation,
can only be evaluated using models based on murine tumors sta-
bly transfected with IDO1 (12, 56). Recent evidence in mouse
models indicates that both tumor cells and host-derived cells
contribute to IDO1-mediated immune resistance to anti-CTLA4
therapy (56).
The last pattern of IDO1 expression observed in human tumors,
which is particularly striking in kidney cancer, is restricted to
endothelial cells (38). As discussed above, the biological func-
tion of endothelial IDO1 remains to be defined. Intriguingly,
endothelial IDO1 expression in kidney tumors was reported to
be associated with a better prognosis, while in most other tumor
types, IDO1 expression is associated with a worse clinical outcome
(57). Of note, as opposed to many other tumor types, T-cell infil-
tration of kidney tumors is associated with a bad prognosis (58).
Further studies will be required to understand those unexpected
features of kidney tumors.
In tumor-draining lymph nodes
Several publications have reported increased proportions of
IDO1-expressing DC in tumor-draining lymph nodes (TDLN) as
compared to normal lymph nodes, mostly in mouse tumor mod-
els but also in human tumors, suggesting an important role of
TDLNs in shaping tumoral immune tolerance (59–62). However,
the recent study mentioned above, which used a carefully vali-
dated monoclonal antibody against human IDO1, did not confirm
an increased proportion of IDO1-expressing DC in a series of 30
human TDLNs obtained from human melanomas and breast car-
cinomas: these TDLNs expressed IDO1 at the same level as normal
lymph nodes (38). These results suggest that the IDO1 expression
that is relevant to tumor immunosuppression is located at the
tumor site rather than in TDLNs. This is in line with recent find-
ings showing that the use of IDO1 inhibitors in a mouse model
barely affected the priming of new anti-tumor T-cells, but strongly
reactivated effector T-cells in situ at the tumor site (34).
INDOLEAMINE 2,3-DIOXYGENASE 2
Indoleamine 2,3-dioxygenase 2 was identified based on its struc-
tural homology with IDO1 (16, 17). The corresponding genes are
highly homologous and located adjacent to each other on the same
chromosome, suggesting that they resulted from gene duplication.
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Both proteins share 43% identity at the amino acid level, including
conserved residues that are important for IDO1 enzymatic activ-
ity. IDO2 is less well characterized than IDO1. Even though IDO2
has been reported to have enzymatic l-tryptophan degradation
activity in vitro (17, 63), its Km for this amino acid is much higher
than that of IDO1 and TDO, around 6.8 and 12 mM for the human
and mouse enzymes, respectively (30, 64). These values are more
than a 100-fold higher than the physiological l-tryptophan con-
centrations, making it unlikely that IDO2 plays a direct role in the
degradation of this amino acid. They rather suggest that IDO2 has
a different natural substrate (63).
Constitutive expression of Ido2 mRNA and protein has been
detected in mouse kidney, liver, epididymis and brain (16, 17,
65). Upregulation by inflammatory stimuli was observed in vitro
in murine DCs and mesenchymal stem cells treated with IFNγ,
and in vivo in brain following Toxoplasma gondii infection (17,
66–68). Ido2-knockout mice have a normal embryologic develop-
ment and do not show major phenotypic abnormalities, but some
aspects of their inflammatory and immune response to antigenic
stimulation are reduced, including skin contact hypersensitivity
reactions, generation of regulatory T-cells, and production of pro-
inflammatory cytokines (69). Ido2-/- mice also display decreased
joint inflammation in a mouse model of rheumatoid arthritis
(70). These experimental observations are difficult to reconcile
with the proposed model of IDO2 functioning as an immunosup-
pressive enzyme, and suggest a more subtle immunoregulatory
role for IDO2, also in line with its genetic epistatic interaction
with IDO1, suggested by the altered IDO2 splicing observed in
IDO1-knockout mice (69).
In contrast with the mouse, little is known about IDO2 expres-
sion and function in humans. This assessment is rendered difficult
by the lack of a strictly validated antibody and by the complexity of
human IDO2 transcription. The human IDO2 gene contains two
functional polymorphisms in its coding sequence. The R248W
polymorphism drastically reduces the measured enzymatic activ-
ity of IDO2, and the Y359X polymorphism generates a truncated,
enzymatically inactive protein. The high prevalence of these poly-
morphic alleles results in a non-functional IDO2 enzyme in up
to 50% of persons (17). In addition, the IDO2 gene generates at
least five alternative transcripts, with only one encoding the full
IDO1-related protein. IDO2 mRNA was detected by RT-PCR in
liver, small intestine, spleen, placenta, thymus, lung, brain, kidney,
and colon, but the full-length transcript only in placenta and brain
(17). Expression of the IDO2 gene was detected by RT-PCR in cir-
culating myeloid DC and pDC and in in vitro-matured MoDC (48,
71). However, it is not known whether the detected IDO2 tran-
scripts encoded a functional IDO2 protein, as the PCR primers
were chosen to amplify exons 9 and 10, which are present in all
5 IDO2 transcripts. Using PCR conditions that amplify exons
4–9, which are only present in the full-length IDO2-encoding
mRNA, we failed to detect IDO2 expression in in vitro-matured
MoDC (38).
There are insufficient experimental arguments to support the
view that IDO2 is expressed in human tumors. Transcription of
IDO2 was detected by RT-PCR in a high proportion of a small
number of gastric, colon, and renal carcinoma samples, as well
as in several tumor cell lines treated with IFNγ, but again using
primers amplifying exons 9 and 10 (72). The IDO2 protein was
detected by Western blot in three IFNγ-incubated tumor cell lines
(73). However, despite the fact that one of these lines was derived
from a patient homozygous for the Y359X polymorphism, which
results in a truncated protein, the size of the corresponding IDO2
band on the immunoblot was identical to the two others, raising
doubts about the specificity of the antibody used. In addition, it is
unclear whether this antibody was directed against IDO2 or IDO1.
In the same study, IDO2 was detected by immunohistochemistry
in the tumor cells from 12 out of 12 pancreatic carcinoma samples,
but not in normal pancreatic tissue, using an anti-IDO2 poly-
clonal antibody. Here also, the antibody stained tumor samples
from Y359X homozygous patients. Its specificity controls were
not provided.
Our whole transcriptome analysis retrieved from public RNA-
Seq databases displayed in Figure 1C shows that, among healthy
human tissues, only liver, testis, and thyroid express the IDO2
gene, whereas the overwhelming majority of human tumor sam-
ples (>99%) are negative. Because these data do not take the
complexity of the alternative splicing of IDO2 transcripts into
consideration, we verified the absence of IDO2-matched RNA-
Seq reads in 20 melanoma metastases sequenced in our laboratory
(data not shown). We also confirmed the absence of detectable
IDO2 expression by RT-qPCR in 128 human tumor samples and 25
human tumor cell lines of various histological types using primers
amplifying exons 4–9 (data not shown).
Altogether, the frequent occurrence of non-functional IDO2
alleles in the population, the lack of experimental evidence for a
biologically relevant tryptophan catalyzing activity of IDO2 and
the absence of detectable IDO2 expression in most tumors make
it highly unlikely that IDO2 plays a significant role in tryptophan-
related tumoral resistance against immune rejection in humans.
This is supported by the observed trend toward increased overall
survival in patients with wild-type IDO2 compared to patients
with heterozygous or homozygous polymorphisms that ablate
IDO2 activity, in a recent study of brain metastatic patients
receiving radiotherapy combined with chloroquine (74).
SUMMARY
Three enzymes with different features have been implicated in
the first step of tryptophan degradation along the kynurenine
pathway. TDO is a tetrameric enzyme expressed at a high level
in the liver, and responsible for degrading dietary tryptophan
and maintaining constant levels of blood tryptophan. Besides this
physiological role, which is supported by a high Km and a pos-
itive regulation of TDO by tryptophan, TDO appears to have
an immunoregulatory role, probably mediated mostly by tryp-
tophan catabolites. In contrast, IDO1 is an unrelated monomeric
enzyme, whose expression is mostly inducible in most tissues, and
which plays a key role in immunoregulation and the retrocontrol
of immune responses. Its low Km allows IDO1 to effectively deplete
tryptophan in the local microenvironment and thereby impair T-
cell mediated immune responses. Both IDO1 and – albeit less
frequently – TDO are expressed in human tumors and appear to
play a role in tumoral immune resistance, which warrants ongoing
drug discovery efforts aimed at the clinical development of IDO
and TDO inhibitors for cancer therapy. Much less is known about
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the role of IDO2, the third enzyme of the pathway. IDO2 appears to
be expressed at a low level in the liver, testis and thyroid. It is not sig-
nificantly expressed in human tumors. The tryptophan-degrading
activity of IDO2 is particularly low, with a Km at least 100-fold
higher than the physiological concentration of tryptophan. This,
together with the frequent occurrence of polymorphisms affecting
the assumed catalytic activity of human IDO2, makes it unlikely
that IDO2 by itself plays a direct role in tryptophan catabolism,
but rather supports another function for this protein.
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